The global antinuclear antibody test market revenue was around US$ 1.4 billion in 2022 and is estimated to reach US$ 4.92 billion by 2031, growing at a compound annual growth rate (CAGR) of 15% during the forecast period from 2023 to 2031.
Antinuclear antibody (ANA) testing is done to decide whether any autoimmune disorders affect the body's organs and tissues. These tests peek for antinuclear antibodies in the blood serum. The human immune system creates antibodies, that resist foreign invaders like bacteria and viruses.
Market Driving Factors
Various new research analyses utilizing immunofluorescence in the anti-nuclear antibody assay aid in diagnosing various diseases more effectively, and it is predicted to create a positive impact on the market. For instance, in January 2022, according to the analysis published by Arthritis Research & Therapy, saliva from patients with systemic lupus erythematosus (SLE) was tested for ANA using immunofluorescence (IF). It revealed that when these patients were compared to healthy controls, their salivary ANA IF intensities were significantly greater. As a result, increasing R&D activities specifying the advantages of immunofluorescence tests will boost the market growth.
The increasing demand for reagents and assay kits increases the total assay performance which is estimated to drive market growth. This is mainly owing to the that they assist create standardized workflows to aid researchers in multiple fields. As a result, there are standard reagents that assist achieve accurate and efficient outcomes.
Higher diagnostic errors associated with antibody tests are predicted to limit the market growth.
Regional Analysis
North America dominated the market in terms of growth rate and is expected to maintain its dominance. This can be attributed to the increased prevalence of autoimmune illnesses in the region. In addition, as the population increases, the probability of developing an autoimmune disease also increases, which is estimated to propel the market growth in the region.
Asia Pacific is estimated to dominate the market in terms of the fastest revenue. This is due to the surging prevalence of autoimmune diseases and the increasing demand for proper diagnosis. Furthermore, rising awareness about the early diagnosis and treatment of autoimmune disorders is estimated to boost the market. Furthermore, the surging government initiatives to enhance healthcare infrastructure and the rising healthcare expenditure are estimated to propel the market expansion in the region.
Segmentation Insights
Product Insight
The reagents & assay kits segment is predicted to dominate the market in terms of the rate. This is generally owing to the test kits are mainly utilized in drug discovery and development, life science research, environmental monitoring, the analysis of disease pathways, and for several research and development purposes such as screening for potential drug candidates and estimating biopharmaceutical production procedures. Additionally, such a wide array of applications is estimated to drive the market.
Technique Insight
The ELISA segment dominates the market in terms of the largest shares. This is because ELISA or enzyme-linked immunosorbent assay (ELISA) based test is utilized to discover antibodies that the body produces to combat antigens or foreign substances fast. As a result, such a process of antinuclear antibody test in the ELISA is estimated to create opportunities in the market.
Application Insight
The rheumatoid arthritis segment dominated the market in terms of the largest shares. This can be mainly attributed to the surge in the geriatric population worldwide and the incidence of rheumatoid arthritis.
End-Use Insight
The hospital segment is anticipated to dominate the market in terms of revenue. This is primarily due to the surge in outpatient services, patient satisfaction, and improved home care facilities provided by hospitals.
Prominent Companies
Segmentation Outline
The global antinuclear antibody test market segmentation focuses on the Product, Technique, Application, End-Use, and Region.
By Product
By Technique
By Application
By End-Use
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL ANTINUCLEAR ANTIBODY TEST MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: ANTINUCLEAR ANTIBODY TEST MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL ANTINUCLEAR ANTIBODY TEST MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL ANTINUCLEAR ANTIBODY TEST MARKET, BY PRODUCT
5.1 OVERVIEW
5.2 REAGENTS & ASSAY KITS
5.3 SYSTEMS
5.4 SOFTWARE & SERVICES
6 GLOBAL ANTINUCLEAR ANTIBODY TEST MARKET, BY TECHNIQUE
6.1 OVERVIEW
6.2 ELISA
6.3 IMMUNOFLUORESCENCE ASSAY
6.4 MULTIPLEX ASSAY
7 GLOBAL ANTINUCLEAR ANTIBODY TEST MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 RHEUMATOID ARTHRITIS
7.3 SYSTEMIC LUPUS ERYTHEMATOSUS
7.4 SJOGREN’S SYNDROME
7.5 SCLERODERMA
7.6 OTHERS
8 GLOBAL ANTINUCLEAR ANTIBODY TEST MARKET, BY END-USE
8.1 OVERVIEW
8.2 HOSPITALS
8.3 CLINICAL LABORATORIES
8.4 PHYSICIAN OFFICE LABORATORIES
8.5 OTHERS
9 GLOBAL ANTINUCLEAR ANTIBODY TEST MARKET, BY GEOGRAPHY
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 NORTH AMERICA MARKET SNAPSHOT
9.2.2 U.S.
9.2.3 CANADA
9.2.4 MEXICO
9.3 EUROPE
9.3.1 EUROPE MARKET SNAPSHOT
9.3.2 WESTERN EUROPE
9.3.2.1 THE UK
9.3.2.2 GERMANY
9.3.2.3 FRANCE
9.3.2.4 ITALY
9.3.2.5 SPAIN
9.3.2.6 REST OF WESTERN EUROPE
9.3.3 EASTERN EUROPE
9.3.3.1 POLAND
9.3.3.2 RUSSIA
9.3.3.3 REST OF EASTERN EUROPE
9.4 ASIA PACIFIC
9.4.1 ASIA PACIFIC MARKET SNAPSHOT
9.4.2 CHINA
9.4.3 JAPAN
9.4.4 INDIA
9.4.5 AUSTRALIA & NEW ZEALAND
9.4.6 ASEAN
9.4.7 REST OF ASIA PACIFIC
9.5 MIDDLE EAST & AFRICA
9.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
9.5.2 UAE
9.5.3 SAUDI ARABIA
9.5.4 SOUTH AFRICA
9.5.5 REST OF MEA
9.6 SOUTH AMERICA
9.6.1 SOUTH AMERICA MARKET SNAPSHOT
9.6.2 BRAZIL
9.6.3 ARGENTINA
9.6.4 REST OF SOUTH AMERICA
10 GLOBAL ANTINUCLEAR ANTIBODY TEST MARKET COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPANY MARKET RANKING
10.3 KEY DEVELOPMENT STRATEGIES
10.4 COMPETITIVE DASHBOARD
10.5 PRODUCT MAPPING
10.6 TOP PLAYER POSITIONING, 2022
10.7 COMPETITIVE HEATMAP
10.8 TOP WINNING STRATEGIES
11 COMPANY PROFILES
11.1 IMMUNO CONCEPTS NA LTD.
11.1.1 OVERVIEW
11.1.2 FINANCIAL PERFORMANCE
11.1.3 PRODUCT OUTLOOK
11.1.4 KEY DEVELOPMENTS
11.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.2 ZEUS SCIENTIFIC INC.
11.2.1 OVERVIEW
11.2.2 FINANCIAL PERFORMANCE
11.2.3 PRODUCT OUTLOOK
11.2.4 KEY DEVELOPMENTS
11.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.3 BIO-RAD LABORATORIES INC.
11.3.1 OVERVIEW
11.3.2 FINANCIAL PERFORMANCE
11.3.3 PRODUCT OUTLOOK
11.3.4 KEY DEVELOPMENTS
11.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.4 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG
11.4.1 OVERVIEW
11.4.2 FINANCIAL PERFORMANCE
11.4.3 PRODUCT OUTLOOK
11.4.4 KEY DEVELOPMENTS
11.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.5 THERMO FISHER SCIENTIFIC INC.
11.5.1 OVERVIEW
11.5.2 FINANCIAL PERFORMANCE
11.5.3 PRODUCT OUTLOOK
11.5.4 KEY DEVELOPMENTS
11.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.6 ERBA DIAGNOSTICS MANNHEIM GMBH
11.6.1 OVERVIEW
11.6.2 FINANCIAL PERFORMANCE
11.6.3 PRODUCT OUTLOOK
11.6.4 KEY DEVELOPMENTS
11.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.7 ANTIBODIES INCORPORATED
11.7.1 OVERVIEW
11.7.2 FINANCIAL PERFORMANCE
11.7.3 PRODUCT OUTLOOK
11.7.4 KEY DEVELOPMENTS
11.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.8 INOVA DIAGNOSTICS INC.
11.8.1 OVERVIEW
11.8.2 FINANCIAL PERFORMANCE
11.8.3 PRODUCT OUTLOOK
11.8.4 KEY DEVELOPMENTS
11.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.9 TRINITY BIOTECH PLC.
11.9.1 OVERVIEW
11.9.2 FINANCIAL PERFORMANCE
11.9.3 PRODUCT OUTLOOK
11.9.4 KEY DEVELOPMENTS
11.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved